Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib

References

• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
   PubMed Web of Science ®Google Scholar
• AtzoriMGTentoriLRuffiniFThe anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cellsJ Exp Clin Cancer Res201736110628797294
   PubMedGoogle Scholar
• WellsSAGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol201028576777220065189
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepa-tocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• SaneDCAntonLBrosnihanKBAngiogenic growth factors and hypertensionAngiogenesis20047319320115609074
   PubMedGoogle Scholar
• BhargavaPVEGF kinase inhibitors: how do they cause hypertension?Am J Physiol Regul Integr Comp Physiol20092971R1R519439616
   PubMed Web of Science ®Google Scholar
• MouradJJdes GuetzGDebbabiHLevyBIBlood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculationAnn Oncol200819592793418056916
   PubMed Web of Science ®Google Scholar
• GoodwinRDingKSeymourLTreatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group study BR24Ann Oncol201021112220222620427348
   PubMed Web of Science ®Google Scholar
• ZhongJAliANVoloschinADBevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumabCancer201512191456146225557543
   PubMed Web of Science ®Google Scholar
• JainLSissungTMDanesiRHypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibJ Exp Clin Cancer Res20102919520630084
   PubMedGoogle Scholar
• LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with Chemotherapy-Refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• HuXCaoJHuWMulticenter phase II study of apatinib in non-triple-negative metastatic breast cancerBMC Cancer201414182025376790
   PubMedGoogle Scholar
• HuXZhangJXuBMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInt J Cancer201413581961196924604288
   PubMed Web of Science ®Google Scholar
• LiuXQinSWangZEarly presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyJ Hematol Oncol201710115328870253
   PubMed Web of Science ®Google Scholar
• ZhangLShiMHuangCLiuXA phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimensJ Clin Oncol201215Suppl7548
   Google Scholar
• XuJLiuXYangSZhangXShiYApatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective studyOnco Targets Ther2017104989499529075129
   PubMed Web of Science ®Google Scholar
• LiFZhuTCaoBWangJLiangLApatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistanceEur J Cancer20178418419228822888
   PubMed Web of Science ®Google Scholar
• PengYCuiHLiuZApatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case reportOnco Targets Ther2017102289229528490886
   PubMed Web of Science ®Google Scholar
• SongZYuXLouGShiXZhangYSalvage treatment with apatinib for advanced non-small-cell lung cancerOnco Targets Ther2017101821182528367065
   PubMed Web of Science ®Google Scholar
• ZengDXWangCGLeiWHuangJAJiangJHEfficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinomaOncotarget2017839662486625329029508
   PubMedGoogle Scholar
• FangSCZhangHTZhangYMXieWPApatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinomaOnco Targets Ther20171044745228176910
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteCommon Terminology Criteria for Adverse Events, Version 4.0Bethesda, MDNational Cancer Institute, National Institutes of Health Department of Health and Human Services2009
   Google Scholar
• FanMZhangJWangZPhosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapyBreast Cancer Res Treat2014143114115124292957
   PubMed Web of Science ®Google Scholar
• DahlbergSESandlerABBrahmerJRSchillerJHJohnsonDHClinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECoG 4599J Clin Oncol201028694995420085937
   PubMed Web of Science ®Google Scholar
• RiniBISchillerJHFruehaufJPDiastolic blood pressure as a biomarker of axitinib efficacy in solid tumorsClin Cancer Res201117113841384921531811
   PubMed Web of Science ®Google Scholar
• MaitlandMLBakrisGLBlackHRInitial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsJ Natl Cancer Inst2010102959660420351338
   PubMedGoogle Scholar
• RiniBICohenDPLuDRHypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibJ Natl Cancer Inst2011103976377321527770
   PubMed Web of Science ®Google Scholar
• RiniBIMelicharBUedaTAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialLancet Oncol201314121233124224140184
   PubMed Web of Science ®Google Scholar
• LiJZhaoXChenLSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer201010152920923544
   PubMedGoogle Scholar
• LambrechtsDMoisseMDelmarPGenetic markers of bevacizumab-induced hypertensionAngiogenesis201417368569424558090
   PubMed Web of Science ®Google Scholar
• MoritaSUeharaKNakayamaGAssociation between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancerCancer Chemother Pharmacol201371240541123161411
   PubMed Web of Science ®Google Scholar
• SchneiderBPWangMRadovichMECOG 2100Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECoG 2100J Clin Oncol200826284672467818824714
   PubMed Web of Science ®Google Scholar
• GampenriederSPRomederFMußCHypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysisAnticancer Res201434122723324403467
   PubMed Web of Science ®Google Scholar